Significant overexpression of urokinase‐type plasminogen activator in pancreatic adenocarcinoma using real‐time quantitative reverse transcription polymerase chain reaction
暂无分享,去创建一个
Yong Li | C. Scarlett | J. Samra | A. Gill | B. Allen | Ross C. Smith | A. Nielsen | Barry J. Allen
[1] H. Kwaan. The plasminogen-plasmin system in malignancy , 1992, Cancer and Metastasis Reviews.
[2] M. Caputi,et al. Urokinase‐mediated posttranscriptional regulation of urokinase‐receptor expression in non small cell lung carcinoma , 2003, International journal of cancer.
[3] S. Dixon,et al. Noncatalytic domain of uPA stimulates human extravillous trophoblast migration by using phospholipase C, phosphatidylinositol 3-kinase and mitogen-activated protein kinase. , 2003, Experimental cell research.
[4] I. Bartenjev,et al. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma. , 2003, Oncology reports.
[5] N. Brünner,et al. Immunoassays of urokinase (uPA) and its type-1 inhibitor (PAI-1) in detergent extracts of breast cancer tissue. , 2003, European journal of cancer.
[6] E. Baker,et al. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. , 2003, European journal of cancer.
[7] M. Ranson,et al. Preclinical studies of targeted α therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2 , 2003, British Journal of Cancer.
[8] H. Höfler,et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Czekay,et al. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins , 2003, The Journal of cell biology.
[10] G. Rice,et al. Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach , 2003, Proteomics.
[11] K. Preissner,et al. Binding of Urokinase Plasminogen Activator to gp130 via a Putative Urokinase-Binding Consensus Sequence , 2003, Biological chemistry.
[12] J. Schneider,et al. Accumulation of uPA – PAI-1 complexes inside the tumour cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer , 2003, British Journal of Cancer.
[13] Megumi Baba,et al. Urokinase‐type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer , 2003, Cancer science.
[14] I. Bièche,et al. Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer. , 2002, Anticancer research.
[15] Helmut Burtscher,et al. Identification of rat pancreatic carcinoma genes associated with lymphogenous metastasis. , 2002, Anticancer research.
[16] M. Ranson,et al. 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model , 2002, British Journal of Cancer.
[17] S. Rosenberg. New developments in the urokinase-type plasminogen activator system , 2001, Expert opinion on therapeutic targets.
[18] T. Gress,et al. TGF‐β–induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase‐2 and the urokinase plasminogen activator system , 2001, International journal of cancer.
[19] M. Pfaffl,et al. A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.
[20] R. Rasmussen. Quantification on the LightCycler , 2001 .
[21] S. Bustin. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. , 2000, Journal of molecular endocrinology.
[22] P. Andreasen,et al. The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.
[23] Douglas B. Evans,et al. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA , 1999, Oncogene.
[24] N. Lemoine,et al. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. , 1998, Cancer research.
[25] T. Nakamura,et al. Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met. , 1998, The American journal of pathology.
[26] D. Berger,et al. Angiostatin generation by human pancreatic cancer. , 1998, The Journal of surgical research.
[27] F. Real,et al. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro , 1998, Oncogene.
[28] M. Duffy,et al. The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.
[29] H. Friess,et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. , 1997, British Journal of Cancer.
[30] V. Tkachuk,et al. REGULATION AND ROLE OF UROKINASE PLASMINOGEN ACTIVATOR IN VASCULAR REMODELLING , 1996, Clinical and experimental pharmacology & physiology.
[31] B. Nielsen,et al. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[32] E. Hedley‐Whyte,et al. Prognostic role of urokinase-type plasminogen activator in human gliomas. , 1995, The American journal of pathology.
[33] H. Verspaget,et al. Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. , 1995, European journal of cancer.
[34] A. Nakao,et al. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. , 1993, The American journal of gastroenterology.
[35] F. Jänicke,et al. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. , 1992, Biological chemistry Hoppe-Seyler.
[36] R. Tsuchiya,et al. UICC and Japanese stage classifications for carcinoma of the pancreas , 1991, International journal of pancreatology : official journal of the International Association of Pancreatology.